Skip to main content
. 2020 Mar 9;4(5):906–919. doi: 10.1182/bloodadvances.2019001188

Figure 5.

Figure 5.

JNJ-67571244 mediates reduction of CD33+leukocytes in cynomolgus monkeys. Cynomolgus monkeys were treated with a single IV dose of control (vehicle), 0.05, 0.2, or 1 mg/kg of JNJ-67571244. (A) JNJ-67571244 concentration over time profiles. (B) T-cell activation (% CD25+ on CD8+ T cells) in peripheral blood. (C) The effect of JNJ-67571244 on granulocytes (neutrophils). (D) The effect of JNJ-67571244 on monocytes.